Kenvue (NYSE:KVUE) Upgraded at Piper Sandler

Kenvue (NYSE:KVUE) was upgraded by equities research analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a report issued on Monday,Briefing.com Automated Import reports. The firm currently has a $26.00 price objective on the stock, up from their prior price objective of $21.00. Piper Sandler’s target price points to a potential upside of 22.64% from the stock’s previous close.

A number of other equities analysts have also issued reports on KVUE. Barclays upgraded shares of Kenvue to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. JPMorgan Chase & Co. increased their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Finally, Bank of America upped their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $23.09.

Kenvue Price Performance

Shares of KVUE opened at $21.20 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue has a 1-year low of $17.67 and a 1-year high of $24.46. The stock has a market cap of $40.65 billion, a PE ratio of 38.55, a price-to-earnings-growth ratio of 2.02 and a beta of 1.46. The firm has a fifty day moving average price of $22.81 and a 200 day moving average price of $21.51.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the previous year, the business earned $0.31 EPS. As a group, sell-side analysts anticipate that Kenvue will post 1.07 EPS for the current year.

Institutional Investors Weigh In On Kenvue

Several institutional investors have recently made changes to their positions in the stock. Leo Wealth LLC lifted its stake in shares of Kenvue by 0.3% in the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after purchasing an additional 481 shares during the period. Alerus Financial NA lifted its position in shares of Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after acquiring an additional 491 shares during the period. Massmutual Trust Co. FSB ADV boosted its stake in shares of Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after acquiring an additional 492 shares in the last quarter. Wolff Wiese Magana LLC boosted its stake in shares of Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after acquiring an additional 501 shares in the last quarter. Finally, Marathon Capital Management grew its holdings in shares of Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after acquiring an additional 514 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.